Paul Schwarzenberger
Research Subjects
Paul Schwarzenberger has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Jay K. Kolls
Gene Therapy Program, Louisiana State University Health Sciences Center of New Orleans, 533 Bolivar CRSB, New Orleans, Louisiana 70112
4 shared publicationsChris Theodossiou
3 shared publicationsWeitao Huang
Gene Therapy Program, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70122, USA
3 shared publicationsPeter Oliver
Gene Therapy Program,1 Department of Medicine,2 Department of Pediatrics,4 and Department of Anatomy,5 Louisiana State University Health Sciences Center of New Orleans, and Bone Marrow Transplantation Program, Tulane University,3 New Orleans, Louisiana
2 shared publicationsVincent La Russa
2 shared publicationsAnna Fariss
1 shared publication
Latest Publications
- 1 August 2004
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (4) , 395-399
Dose Escalation of Docetaxel Concomitant With Hypofractionated, Once Weekly Chest Radiotherapy for Non-Small-Cell Lung Cancer
Hypofractionated chest radiotherapy has been used as an alternative when standard fractionated schedules are neither practical nor feasible. To explore docetaxel as radiosensitizer in a hypofractionated chest irradiation schedule, a docetaxel dose escalation study was conducted in which 26 patients with advanced non-small-cell lung cancer (NSCLC) (stages III and IV) were enrolled. Docetaxel was administered 24 hours prior to irradiation (starting dose 10mg/m2; escalating in 5mg/m2 increments). Radiation was administered at 500 cGy (one fraction) once/wk for 10 consecutive weeks (5000 cGy total). The docetaxel dose was escalated up to 45 mg/m2/wk. The treatment was well tolerated over 10 consecutive weeks without requiring dose reductions or interruptions. Toxicities were mainly docetaxel related. One of 19 evaluable patients had a complete radiographic response within the radiation treatment port, 13 had a partial response, and 5 had stable disease. No patient recurred within the radiation field. Three patients who underwent surgical resection following treatment were pathologically down staged to stage I. This trial of a small group of patients supports, in selected patients, synchronous administration of effective hypofractionated, radiosensitized radiation therapy and optimized systemic chemotherapy.
- 1 August 2004
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (4) , 395-399
Dose Escalation of Docetaxel Concomitant With Hypofractionated, Once Weekly Chest Radiotherapy for Non-Small-Cell Lung Cancer
Hypofractionated chest radiotherapy has been used as an alternative when standard fractionated schedules are neither practical nor feasible. To explore docetaxel as radiosensitizer in a hypofractionated chest irradiation schedule, a docetaxel dose escalation study was conducted in which 26 patients with advanced non-small-cell lung cancer (NSCLC) (stages III and IV) were enrolled. Docetaxel was administered 24 hours prior to irradiation (starting dose 10mg/m2; escalating in 5mg/m2 increments). Radiation was administered at 500 cGy (one fraction) once/wk for 10 consecutive weeks (5000 cGy total). The docetaxel dose was escalated up to 45 mg/m2/wk. The treatment was well tolerated over 10 consecutive weeks without requiring dose reductions or interruptions. Toxicities were mainly docetaxel related. One of 19 evaluable patients had a complete radiographic response within the radiation treatment port, 13 had a partial response, and 5 had stable disease. No patient recurred within the radiation field. Three patients who underwent surgical resection following treatment were pathologically down staged to stage I. This trial of a small group of patients supports, in selected patients, synchronous administration of effective hypofractionated, radiosensitized radiation therapy and optimized systemic chemotherapy.
- Top Cited PapersOpen Access
- 1 August 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 190 (3) , 624-631
Requirement of Interleukin‐17A for Systemic Anti–Candida albicansHost Defense in Mice
T cells are required for normal host defense against fungal infection, and individuals with T cell.deficiency syndromes are highly susceptible to fun
- 1 August 2004
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 190 (3) , 624-631
Top Cited PapersOpen AccessRequirement of Interleukin‐17A for Systemic Anti–Candida albicansHost Defense in Mice
T cells are required for normal host defense against fungal infection, and individuals with T cell.deficiency syndromes are highly susceptible to fun
- 16 May 2002
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 85 (S38) , 88-95
Interleukin 17: An example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis
Interleukin 17 (IL‐17) is an essential proinflammatory T‐cell derived cytokine with various biological actions. IL‐17 was found to have a pivotal role in microbial host defense by interconnecting lymphoid and myeloid host defense. It also acts as a stimulatory hematopoietic cytokine by expanding myeloid progenitors and initiating proliferation of mature neutrophils. This article summarizes results to date on IL‐17 research and discusses gene therapy based strategies that were employed to determine its biological functions and significance. A comprehensive working model for IL‐17 is introduced. J. Cell. Biochem. Suppl. 38: 88–95, 2002.
- 16 May 2002
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 85 (S38) , 88-95
Interleukin 17: An example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis
Interleukin 17 (IL‐17) is an essential proinflammatory T‐cell derived cytokine with various biological actions. IL‐17 was found to have a pivotal role in microbial host defense by interconnecting lymphoid and myeloid host defense. It also acts as a stimulatory hematopoietic cytokine by expanding myeloid progenitors and initiating proliferation of mature neutrophils. This article summarizes results to date on IL‐17 research and discusses gene therapy based strategies that were employed to determine its biological functions and significance. A comprehensive working model for IL‐17 is introduced. J. Cell. Biochem. Suppl. 38: 88–95, 2002.
- Open Access
- 1 February 2002
- Published by Taylor & Francis in BioTechniques
- Vol. 32 (2) , 278-286
Chimerism Analysis in Sex-Mismatched Murine Transplantation Using Quantitative Real-Time PCR
Murine experimental stem cell transplantations require the accurate discrimination and quantification of donor cells from host cells. A Y-chromosome-specific, quantitative real-time PCR (kinetic PC...
- 1 February 2002
- Published by Taylor & Francis in BioTechniques
- Vol. 32 (2) , 278-286
Open AccessChimerism Analysis in Sex-Mismatched Murine Transplantation Using Quantitative Real-Time PCR
Murine experimental stem cell transplantations require the accurate discrimination and quantification of donor cells from host cells. A Y-chromosome-specific, quantitative real-time PCR (kinetic PC...
- 1 January 2002
- Published by Taylor & Francis in Cancer Investigation
- Vol. 20 (1) , 124-138
Hematopoietic Stem Cells
- 1 January 2002
- Published by Taylor & Francis in Cancer Investigation
- Vol. 20 (1) , 124-138
Hematopoietic Stem Cells
- 1 November 2001
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (21) , 10393-400
Efficient c-kit Receptor-Targeted Gene Transfer to Primary Human CD34-Selected Hematopoietic Stem Cells
We have previously reported effective gene transfer with a targeted molecular conjugate adenovirus vector through the c-kit receptor in hematopoietic progenitor cell lines. However, a c-kit-targeted recombinant retroviral vector failed to transduce cells, indicating the existence of significant differences for c-kit target gene transfer between these two viruses. Here we demonstrate that conjugation of an adenovirus to a c-kit-retargeted retrovirus vector enables retroviral transduction. This finding suggests the requirement of endosomalysis for successful c-kit-targeted gene transfer. Furthermore, we show efficient gene transfer to, and high transgene expression (66%) in, CD34-selected, c-kit + human peripheral blood stem cells using a c-kit-targeted adenovirus vector. These findings may have important implications for future vector development in c-kit-targeted stem cell gene transfer.
- 1 November 2001
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (21) , 10393-400
Efficient c-kit Receptor-Targeted Gene Transfer to Primary Human CD34-Selected Hematopoietic Stem Cells
We have previously reported effective gene transfer with a targeted molecular conjugate adenovirus vector through the c-kit receptor in hematopoietic progenitor cell lines. However, a c-kit-targeted recombinant retroviral vector failed to transduce cells, indicating the existence of significant differences for c-kit target gene transfer between these two viruses. Here we demonstrate that conjugation of an adenovirus to a c-kit-retargeted retrovirus vector enables retroviral transduction. This finding suggests the requirement of endosomalysis for successful c-kit-targeted gene transfer. Furthermore, we show efficient gene transfer to, and high transgene expression (66%) in, CD34-selected, c-kit + human peripheral blood stem cells using a c-kit-targeted adenovirus vector. These findings may have important implications for future vector development in c-kit-targeted stem cell gene transfer.
- 1 February 2001
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 321 (2) , 129-136
Poly-l-lysine-Based Molecular Conjugate Vectors: A High Efficiency Gene Transfer System for Human Progenitor and Leukemia Cells
- 1 February 2001
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 321 (2) , 129-136
Poly-l-lysine-Based Molecular Conjugate Vectors: A High Efficiency Gene Transfer System for Human Progenitor and Leukemia Cells